BioSpace News Archive

Genetown

Sarepta Therapeutics Announces Exercise of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes Due 2024

Capped call transactions raise the effective conversion price of the notes to $104.88, subject to future adjustments.

November 10, 2017
·
5 min read
Business

Nine-Month Interim Report (Q3) 2017

Sales growth in Europe, North America and International markets showed good progress in line with expectations.

November 10, 2017
·
3 min read
Drug Development

Deciphera Pharmaceuticals Reports Data Analysis From the Ongoing Phase I Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society

The presentation reviews data from the same trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in September 2017.

November 10, 2017
·
8 min read
Business

Medigene Reports Nine Months’ Results 2017

MediGene today released its financial results for the first nine months of 2017.

November 10, 2017
·
4 min read
Business

Fortress Biotech Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights

As of September 30, 2017, Fortress’ consolidated cash, cash equivalents and short-term investments totaled $154.6 million, compared to $88.3 million at December 31, 2016.

November 10, 2017
·
15 min read
Business

Aclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly

Bierly was appointed to Aclaris Therapeutics’ board of directors on October 2015,

November 10, 2017
·
1 min read
Business

Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress

As of September 30, 2017, cash and cash equivalents totaled $96.0 million.

November 10, 2017
·
9 min read
Business

Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results

The Company’s net loss applicable to common shareholders for the three months ended September 30, 2017 was $8.9 million.

November 10, 2017
·
12 min read
Business

Hackensack University Medical Center Collaborates with Novartis on Groundbreaking Pediatric Oncology Immunotherapy Program

Hackensack Meridian Health Hackensack University Medical Center is pleased to announce participation in a groundbreaking pediatric oncology immunotherapy program, provided in collaboration with Novartis Pharma as a member of a network of certified treatment centers.

November 10, 2017
·
4 min read
Business

Immuno-Oncology CRO Secures Macrophage Pharma Agreement

Macrophage Pharma’s immuno-oncology programme with Aquila will incorporate a combination of in vitro, in vivo and ex vivo analyses.

November 10, 2017
·
1 min read